Drug Development Pipeline
QBW276 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase two study to test the safety, tolerability and effectiveness of QBW276 in people with CF was completed in 2018. No further development in CF is planned at this time.
This program was sponsored by Novartis Pharmaceuticals. It was conducted through the Therapeutics Development Network.
Recent QBW276 Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More